StageAcquired | Acquired
About Axcell Biotechnologies
Axcell Biotechnologies is a biopharma company that has developed Spirolept, a vaccine against human leptospirosis marketed in France. In April 2012, Axcell Biotechnologies was acquired by Imaxio. The valuation of Axcell Biotechnologies was undisclosed. Other terms of the deal were not released.
Missing: Axcell Biotechnologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Axcell Biotechnologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Axcell Biotechnologies Frequently Asked Questions (FAQ)
What is Axcell Biotechnologies's latest funding round?
Axcell Biotechnologies's latest funding round is Acquired.
Who are the investors of Axcell Biotechnologies?
Investors of Axcell Biotechnologies include Imaxio.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.